Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Predictors of premature discontinuation of treatment in multiple disease states.

Nantz E, Liu-Seifert H, Skljarevski V.

Patient Prefer Adherence. 2009 Nov 3;3:31-43.

PMID:
19936143
[PubMed]
Free PMC Article
2.

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.

Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.

Clin Ther. 2009 Jun;31 Pt 1:1405-23. doi: 10.1016/j.clinthera.2009.07.006.

PMID:
19698901
[PubMed - indexed for MEDLINE]
3.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
[PubMed - indexed for MEDLINE]
4.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

PMID:
17083854
[PubMed - indexed for MEDLINE]
Free Article
5.

Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies.

Brunton S, Wang F, Edwards SB, Crucitti AS, Ossanna MJ, Walker DJ, Robinson MJ.

Drug Saf. 2010 May 1;33(5):393-407. doi: 10.2165/11319200-000000000-00000.

PMID:
20397739
[PubMed - indexed for MEDLINE]
6.

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.

Beasley CM Jr, Koke SC, Nilsson ME, Gonzales JS.

Clin Ther. 2000 Nov;22(11):1319-30.

PMID:
11117656
[PubMed - indexed for MEDLINE]
7.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
8.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
[PubMed - indexed for MEDLINE]
9.

[Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].

Auxéméry Y.

Encephale. 2012 Oct;38(5):373-80. doi: 10.1016/j.encep.2011.12.003. Epub 2012 Jan 24. Review. French.

PMID:
23062450
[PubMed - indexed for MEDLINE]
10.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34. Epub 2007 Apr 18.

PMID:
17445831
[PubMed - indexed for MEDLINE]
11.

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F.

Drug Saf. 2007;30(5):437-55.

PMID:
17472422
[PubMed - indexed for MEDLINE]
12.

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.

Clin Ther. 2008 Nov;30(11):1988-2004. doi: 10.1016/j.clinthera.2008.11.009. Erratum in: Clin Ther. 2009 Feb;31(2):446. Clin Ther. 2009 Jul;31(7):1617.

PMID:
19108787
[PubMed - indexed for MEDLINE]
13.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
[PubMed - indexed for MEDLINE]
14.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.

J Affect Disord. 2006 Aug;94(1-3):183-9. Epub 2006 Jun 14.

PMID:
16780958
[PubMed - indexed for MEDLINE]
15.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
[PubMed - indexed for MEDLINE]
16.

Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.

Citrome L, Yang R, Glue P, Karayal ON.

Schizophr Res. 2009 Jun;111(1-3):39-45. doi: 10.1016/j.schres.2009.03.009. Epub 2009 Apr 17.

PMID:
19375893
[PubMed - indexed for MEDLINE]
17.

A retrospective pooled analysis of duloxetine safety in 23,983 subjects.

Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L.

Curr Med Res Opin. 2007 Jan;23(1):175-84.

PMID:
17257478
[PubMed - indexed for MEDLINE]
18.

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.

Katz IR, Reynolds CF 3rd, Alexopoulos GS, Hackett D.

J Am Geriatr Soc. 2002 Jan;50(1):18-25.

PMID:
12028242
[PubMed - indexed for MEDLINE]
20.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk